Miyamura H, Kanazawa H, Takahashi Y, Okazaki H, Imaizumi K, Hayashi J, Fukuda J, Oguma F, Sugawara M, Eguchi S
Second Department of Surgery, Niigata University, School of Medicine, Japan.
Nihon Kyobu Geka Gakkai Zasshi. 1990 Aug;38(8):1298-303.
Valve replacements in the right side of the heart (TVR and PVR) were done on 16 patients with congenital heart disease, mainly tetralogy of Fallot and Ebstein anomaly. Including reoperations, 19 operations were performed on them and 20 artificial valves were inserted. Ten mechanical valves (7 St. Jude Medical valves, 3 Starr-Edwards valves) and 10 bioprosthetic valves (7 Carpentier-Edwards valves, 3 Ionescu-Shiley valves) were used. Age at valve replacement ranged from 9 to 52 years (mean 23.0 years), and the follow-up period was 1.28-19.8 years (mean 5.7 years). Including 2 sudden deaths, late death occurred in 4 patients, on all of whom mechanical valve replacements were done at the primary operation. Five-year survival rate of all patients was 76.4 +/- 12.1%, and 10-year survival rate was 63.6 +/- 15.4%. All the patients who received bioprosthesis at the primary operation survived at the time of this follow-up study. On the contrary, long-term results of mechanical valve was unsatisfactory with the 5-year survival of 62.5 +/- 17.1%. In spite of anti-coagulation therapy with warfarin, three patients with mechanical valve complicated thrombotic valves, which necessitated re-operations. Calcified bioprosthetic valve occurred in one patient with I-S valve 8.5 years after the implantation. Five-year complication-free rate was 87.5 +/- 11.7% for bioprosthesis, whereas it was 50.0 +/- 15.8% for mechanical valve (p less than 0.056). It is concluded that the bioprosthesis is the first choice for the valve replacement in the right side of the heart in congenital heart disease.
对16例先天性心脏病患者进行了右心瓣膜置换术(三尖瓣置换术和肺动脉瓣置换术),主要为法洛四联症和埃布斯坦畸形。包括再次手术,共对他们实施了19次手术,植入了20个人工瓣膜。使用了10个机械瓣膜(7个圣犹达医疗瓣膜,3个斯塔尔-爱德华兹瓣膜)和10个生物瓣膜(7个卡彭蒂埃-爱德华兹瓣膜,3个约内斯库-希利瓣膜)。瓣膜置换时的年龄为9至52岁(平均23.0岁),随访期为1.28至19.8年(平均5.7年)。包括2例猝死,4例患者发生晚期死亡,所有这些患者在初次手术时均进行了机械瓣膜置换。所有患者的5年生存率为76.4±12.1%,10年生存率为63.6±15.4%。所有在初次手术时接受生物瓣膜置换的患者在本次随访研究时均存活。相反,机械瓣膜的长期效果不理想,5年生存率为62.5±17.1%。尽管使用华法林进行了抗凝治疗,但3例机械瓣膜患者出现瓣膜血栓形成并发症,需要再次手术。1例植入I-S瓣膜的患者在植入8.5年后出现生物瓣膜钙化。生物瓣膜的5年无并发症发生率为87.5±11.7%,而机械瓣膜为50.0±15.8%(p<0.056)。结论是,生物瓣膜是先天性心脏病右心瓣膜置换的首选。